`
`
`
`
`
`Case 1:18-cv-12029-ADB Document 31 Filed 01/03/19 Page 1 of 3
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`
`TEVA PHARMACEUTICALS
`
`INTERNATIONAL GMBH and
`
`TEVA PHARMACEUTICALS
`
`USA, INC.,
`
`
`
`
`Plaintiffs,
`
`v.
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`ELI LILLY AND COMPANY,
`
`
`
`
`
`
`Defendant.
`
`
`UNOPPOSED MOTION FOR LEAVE TO FILE A SUR-REPLY
`MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANT’S MOTION TO
`TRANSFER, OR, IF NOT TRANSFERRED, THEN TO STAY THIS LITIGATION
`PENDING INTER PARTES REVIEW
`
`Pursuant to Local Rule 7.1(b)(3) of the United States District Court for the District of
`
`
`
`Massachusetts, Plaintiffs Teva Pharmaceuticals International GmbH (“Teva GmbH”) and Teva
`
`Pharmaceuticals USA, Inc. (“Teva USA” and collectively with Teva GmbH, “Teva”) move for
`
`leave to file a five-page sur-reply memorandum of law in further opposition to Defendant Eli
`
`Lilly and Company’s (“Lilly”) Motion To Transfer, Or, If Not Transferred, Then To Stay This
`
`Litigation Pending Inter Partes Review (“Lilly’s Motion”). D. 18. The proposed sur-reply is
`
`attached as Exhibit A hereto.
`
`
`
`Lilly sought leave to file a reply in support of Lilly’s Motion on December 12, 2018. D.
`
`27. This Court granted leave the next day, D. 28, and Lilly filed its reply on December 21, 2018.
`
`D. 29. In its reply, Lilly attaches five new exhibits, and makes certain assertions that warrant a
`
`response. Teva submits that a brief sur-reply memorandum is necessary in order to address the
`
`
`
`
`1
`
`
`
`Case 1:18-cv-12029-ADB Document 31 Filed 01/03/19 Page 2 of 3
`
`
`
`arguments made in Lilly’s reply, and Teva believes that such a sur-reply will assist the Court in
`
`adjudicating Lilly’s Motion. Lilly’s Motion is not yet scheduled for a hearing, and Teva has
`
`attached the proposed sur-reply to this Motion for leave; the requested sur-reply will therefore
`
`neither delay any proceedings nor prejudice either party. Lilly does not oppose the filing of this
`
`Motion.
`
`
`
`WHEREFORE, Teva respectfully requests that this Court grant Teva’s Motion for leave
`
`to file the attached, five-page sur-reply.
`
`Dated: January 3, 2019
`
`
`
`
`
`2
`
`Respectfully submitted,
`
`
`
`/s/ Robert Frederickson III
`
`Douglas J. Kline (BBO# 556680)
`Elaine Herrmann Blais (BBO# 656142)
`Robert Frederickson III (BBO# 670111)
`Alexandra Lu (BBO# 691114)
`Eric Romeo (BBO# 691591)
`Martin C. Topol (BBO# 696020)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`dkline@goodwinlaw.com
`eblais@goodwinlaw.com
`rfrederickson@goodwinlaw.com
`alu@goodwinlaw.com
`eromeo@goodwinlaw.com
`mtopol@goodwinlaw.com
`
`I. Neel Chatterjee (pro hac vice)
`GOODWIN PROCTER LLP
`601 Marshall St.
`Redwood City, CA 94063
`Tel.: (650) 752-3100
`Fax: (650) 853-1038
`nchatterjee@goodwinlaw.com
`
`Natasha Daughtrey (pro hac vice)
`GOODWIN PROCTER LLP
`601 S. Figueroa St.
`
`
`
`
`
`
`
`Case 1:18-cv-12029-ADB Document 31 Filed 01/03/19 Page 3 of 3
`
`Los Angeles, CA 90017
`Tel.: (213) 426-2500
`Fax: (213) 623-1673
`ndaughtrey@goodwinlaw.com
`
`
`Attorneys for Plaintiffs
`
`LOCAL RULE 7.1(a)(2) CERTIFICATION
`
`I, Robert Frederickson III, hereby certify that on January 2, 2019, Teva’s counsel
`conferred via email with Lilly’s counsel regarding the relief requested in this Motion, and that on
`January 3, 2019, Lilly’s counsel stated that Lilly does not oppose this Motion.
`
`
`/s/ Robert Frederickson III
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I, Robert Frederickson III, hereby certify that a copy of the foregoing document, filed
`through the CM/ECF system, will be sent electronically to the registered participants as
`identified on the Notice of Electronic Filing (NEF) and paper copies shall be served by first class
`mail postage prepaid on all counsel of record who are not served through the CM/ECF system on
`January 3, 2019.
`
`
`/s/ Robert Frederickson III
`
`
`
`
`
`
`
`
`3
`
`